| Literature DB >> 17492936 |
Daniela Buglio1, Georgios Georgakis, Anas Younes.
Abstract
The treatment of Hodgkin lymphoma continues to be based on combination chemotherapy and radiation therapy. Although this treatment strategy produces a high cure rate, short- and long-term toxic effects continue to be problematic for young cured patients. In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17492936 DOI： 10.1586/14737140.7.5.735
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN： 1473-7140 Impact factor: 4.512